ReviewPharmaceutics2022
Recent Developments in Heteroatom/Metal-Doped Carbon Dot-Based Image-Guided Photodynamic Therapy for Cancer.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Carbon Dots Meet MRI: Metal Doping for a Smart Contrast Agent Design.International journal of molecular sciences · 2026Review
- Carbon Dots: Emerging Nanomaterials for Ovarian Cancer Diagnosis and Therapy.Current drug targets · 2026Review
- Carbon Quantum Dots as Versatile Nanosystems for Biomedical Innovation: Mechanisms, Applications, and Translational Prospects.British journal of biomedical science · 2026Review
- Surface Modification, Toxicity, and Applications of Carbon Dots to Cancer Theranosis: A Review.Nanomaterials (Basel, Switzerland) · 2025Review
- Potential of Carbon Nanodots (CNDs) in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- Carbon Dot-Based Nanoparticles: A Promising Therapeutic Approach for Glioblastoma.International journal of nanomedicine · 2025Review
- Review
- Carbon dots as a novel photosensitizer for photodynamic therapy of cancer and bacterial infectious diseases: recent advances.Journal of nanobiotechnology · 2024Review
- Effect of Doping Heteroatoms on the Optical Behaviors and Radical Scavenging Properties of Carbon Nanodots.The journal of physical chemistry. C, Nanomaterials and interfaces · 2023Article
- Recent Advances of Photoactive Near-Infrared Carbon Dots in Cancer Photodynamic Therapy.Pharmaceutics · 2023Review
- Nanotechnology Involved in Treating Urinary Tract Infections: An Overview.Nanomaterials (Basel, Switzerland) · 2023Review
- Progress in drug delivery and diagnostic applications of carbon dots: a systematic review.Frontiers in chemistry · 2023Review
- Carbon quantum dots in bioimaging and biomedicines.Frontiers in bioengineering and biotechnology · 2023Review
- Carbonaceous Nanomaterials for Phototherapy of Cancer.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Carbon nanodots (CNDs) are advanced nanomaterials with a size of 2-10 nm and are considered zero-dimensional carbonaceous materials. CNDs have received great attention in the area of cancer theranostics. The majority of review articles have shown the improvement of CNDs for use in cancer therapy and bioimaging applications. However, there is a minimal number of consolidated studies on the currently developed doped CNDs that are used in various ways in cancer therapies. Hence, in this review, we discuss the current developments in different types of heteroatom elements/metal ion-doped CNDs along with their preparations, physicochemical and biological properties, multimodal-imaging, and emerging applications in image-guided photodynamic therapies for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.